| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 328.4 | 51.6 | 283.7 |
| Other income | 1.9 | 2.4 | 1.8 |
| Total income | 328.4 | 51.6 | 283.7 |
| Profit before exceptional items & tax | 31.8 | 1.2 | 26.9 |
| Exceptional items | 1.2 | 1.3 | 2.1 |
| Profit before tax | 33.0 | 2.5 | 28.9 |
| Net profit | 32.3 | -0.0 | 28.3 |
| Operating margin | 10.0% | 4.8% | 10.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.10% |
|---|---|
| Revenue, year on year | +15.80% |
| Operating profit, year on year | +14.70% |
| Operating profit, quarter on quarter | +1366.70% |
BSE results filing, NSE: NATHBIOGEN. Figures extracted from the filing.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹140.13
- Market cap
- ₹266.3 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.3×Sector 28.6×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Investor Presentation: Key Takeaways
Nath Bio-Genes reported strong Q1 FY27 results with Revenue and EBITDA growing 15% and 17% YoY respectively. The company continues to focus on high-yield cotton, maize, and paddy seeds.
Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b). This disclosure provides the updated distribution of shareholding across various investor categories.
Nath Bio-Genes (India) Board Meeting Date
Nath Bio-Genes (India) Ltd has scheduled a board meeting for 29th July 2026 to consider and approve its unaudited financial results for the June quarter.